Announcements Trials
Browse Landscape

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 276Observational 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 2Recurrence 1Neoplasms, Plasma Cell 1

Interventions

Blood Specimen Collection 135Surveys and Questionnaires 132Specimen Handling 57Observation 55Radiotherapy 43Interviews as Topic 35Surgical Procedures, Operative 31Biopsy 30Drug Therapy 30Data Collection 25Magnetic Resonance Spectroscopy 25Nivolumab 21Immune Checkpoint Inhibitors 18Watchful Waiting 18Standard of Care 17Therapeutics 17Immunotherapy 16Magnetic Resonance Imaging 16trastuzumab deruxtecan 14Liquid Biopsy 13Restraint, Physical 13Tomography, X-Ray Computed 13palbociclib 13Radiosurgery 12enzalutamide 12Focus Groups 11Hematologic Tests 11apalutamide 11darolutamide 11pembrolizumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Lenalidomide × 1 year × Clear all
NCT03106324 2025-11-24

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Celgene

Active not recruiting
911 enrolled
Plasma cell

Multiple Myeloma

NCT07206810 2025-10-03

A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients

The First Affiliated Hospital of Soochow University

Completed
419 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT06163040 2025-07-31

A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Bristol-Myers Squibb

Completed
7 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚔